Press Release **For Immediate Release**

Glenmark Generics receives tentative approval from the USFDA for Riluzole 50 mg tablets

July 29, 2010: Glenmark Generics Inc., USA , the United States subsidiary of Glenmark Generics Ltd, announced today that the United States Food and Drug Administration (U.S. FDA) has granted tentative approval for Riluzole 50 mg tablets, the generic version of Rilutek® tablets by Sanofi Aventis US LLC.

Rilutek is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS) and generated sales of USD 47 million for the 12 month period ending March 2010, according to IMS Health.

Based on the tentative approval for Riluzole tablets, Glenmark Generics should be able to launch the product upon patent expiry in June 2013.

Today's approval is the second tentative and fourth final approval granted to Glenmark this month. The Company received final approval on Theophylline ER 400mg and 600mg tablets, Adapalene 0.1% gel, Norethindrone Acetate 5mg tablets and Norethindrone 0.35mg tablets as well as tentative approval on Fluocinonide 0.1% cream.

Glenmark's current portfolio consists of 57 products authorized for distribution in the U.S. marketplace. The Company has 50 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

About Glenmark Generics limited.
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader.

GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

Disclaimer
"Glenmark Generics Limited ("Company") is proposing, subject to market conditions and other considerations, a public issue of its equity shares and has filed a Draft Red Herring Prospectus with SEBI. The Draft Red Herring Prospectus is available on the website of SEBI at www.sebi.gov.in and the respective websites of the BRLMs at www.enam.com and www.kmcc.co.in.

Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled "Risk Factors" of the aforementioned Draft Red Herring Prospectus."

This press release is not an offer of securities for sale in the United States or elsewhere. The shares of Glenmark Generics Limited are not being registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. There will be no public offering of the shares in the United States.

NOT FOR PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA

#####

For further information, please contact:
Jason D'Souza
Glenmark, Mumbai, India
Tel: [+91 22] 40189919
Email : connect@glenmark-generics.com